Hypha is able to screen pure compounds, fractions or extracts in a variety of whole cell anti-microbial assays. We have assembled a panel of pathogenic fungi and bacteria, both gram positive and gram negative, which can be applied to assess anti-microbial activity of client samples.
Cytotoxicity and anti-proliferation screening
We are able to test samples against a panel of cell lines using methods based on those employed by the US National Cancer Institute (NCI), which enables the assessment of mode of effect, i.e., cytotoxicity, anti-proliferation and cell-cycle arrest, based upon the inhibition curve observed.
Coming soon: PolyCYPs™, the first of Hypha Discovery’s products for accessing drug metabolites in a kit format. PolyCYPs™ cytochrome P450 enzymes provide a convenient way in which to generate oxidised metabolites of drugs in a scalable format. For more information on this development, click here for a poster we presented at a recent conference on use of PolyCYP™ enzymes to access and characterise metabolites of tivantinib.
PolyCyp™ and PolyCyps™ are Trademarks of Hypha Discovery Limited.
Contact us to discuss how we can help your project succeed.